Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

Texto completo
Autor(es):
Forlenza, Orestes V. [1, 2] ; Diniz, Breno S. ; Radanovic, Marcia ; Santos, Franklin S. ; Talib, Leda L. ; Gattaz, Wagner F.
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Fac Med, Lab Neurosci LIM 27, Inst Psychiat, BR-05403010 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Lab Neurosci LIM 27, Dept Psychiat, BR-05403010 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: BRITISH JOURNAL OF PSYCHIATRY; v. 198, n. 5, p. 351-356, MAY 2011.
Citações Web of Science: 187
Resumo

Background Two recent clinical studies support the feasibility of trials to evaluate the disease-modifying properties of lithium in Alzheimer's disease, although no benefits were obtained from short-term treatment. Aims To evaluate the effect of long-term lithium treatment on cognitive and biological outcomes in people with amnestic mild cognitive impairment (aMCI). Method Forty-five participants with aMCI were randomised to receive lithium (0.25-0.5mmol/l) (n=24) or placebo (n = 21) in a 12-month, double-blind trial. Primary outcome measures were the modification of cognitive and functional test scores, and concentrations of cerebrospinal fluid (CSF) biomarkers (amyloid-beta peptide (A beta(42)), total tau (T-tau), phosphorylated-tau) (P-tau). Trial registration: NCT01055392. Results Lithium treatment was associated with a significant decrease in CSF concentrations of P-tau (P=0.03) and better perform-ance on the cognitive subscale of the Alzheimer's Disease Assessment Scale and in attention tasks. Overall tolerability of lithium was good and the adherence rate was 91%. Conclusions The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease. (AU)

Processo FAPESP: 02/13633-7 - Metabolismo de fosfolípides em doenças neuropsiquiátricas
Beneficiário:Wagner Farid Gattaz
Modalidade de apoio: Auxílio à Pesquisa - Temático